BioNTech ve 2. čtvrtletí vykázal tržby 105,6 milionu EUR, téměř o 60 % méně meziročně, a upravenou ztrátu 2,22 EUR na akcii. Firma dál spoléhá na mRNA pipeline mimo vakcínu Comirnaty.
BioNTech (BNTX +1.54%) has lagged the market this year. The company's shares have climbed just 6% as of writing, compared with the S&P 500's 12% gain. The biotech's performance looks even worse once we zoom out. Over the past five years, BioNTech has lost 70% of its value. Could BioNTech bounce back soon, or is the company more likely to continue sinking over the next few years? Let's find out whether it's time to buy the stock after years of underperformance.
Image source: Getty Images.
What's going on with BioNTech? BioNTech developed Comirnaty, a leading coronavirus vaccine, in combination with Pfizer (PFE +1.72%). This product was highly popular in the first few years of the pandemic. It generated almost $38 billion in sales at its peak and helped BioNTech post strong financial performances. However, the pandemic waned, demand for the vaccine declined, and some governments made it harder for people to get vaccinated. As a result, Comirnaty's sales have been unimpressive over the past few years.
That's why BioNTech has been lagging the market. In the second quarter, the company's revenue was 105.6 million euros ($122.7 million), down almost 60% year over year. The biotech's adjusted loss per share was €2.22 ($2.58), worse than the €1.45 ($1.68) loss per share recorded in the year-ago period. BioNTech will likely continue generating some revenue from its coronavirus vaccine franchise, but it is unlikely to be a meaningful, consistent growth driver in the medium term. So, the company needs to look elsewhere for growth.
A landmark clinical trial win BioNTech stock was in the red year-to-date until an important clinical trial win sent it soaring. Of note, it wasn't BioNTech's own clinical success. It was Moderna's (MRNA -2.21%) and Merck's (MRK +1.26%). The two corporations are collaborating to develop intismeran autogene, a personalized cancer vaccine. In a phase 3 study, intismeran autogene, in combination with Keytruda, significantly reduced the risk of recurrence and death in patients with melanoma compared to Keytruda alone. This clinical win showed the potential of Moderna's mRNA vaccine platform beyond infectious diseases and into the lucrative oncology market.
Premium Feature
Moneyball Superscore
68/100
Today's Change
(
1.54
%) $
1.58
Current Price
$
103.52
BioNTech, another company that specializes in mRNA vaccines, suddenly became more attractive to many investors. BioNTech has several mRNA-based candidates in phase 2 or phase 3 studies. For instance, the company's BNT113 is being developed for head and neck cancer, while BNT116 is being investigated in patients with lung cancer. Over the next five years, BioNTech could record important clinical and regulatory wins, significantly improve its approved portfolio, and post much better financial results.
Perhaps BioNTech's most promising candidate is pumitamig, a cancer medicine it is developing in collaboration with Bristol Myers Squibb (BMY +0.90%). Pumitamig is a bispecific antibody, a newer class of drugs that could become increasingly important in oncology. BioNTech is hoping pumitamig can become a pipeline in a drug: The medicine is being developed to treat cancers of the lung, breast, liver, colon, and rectum, and more. Clinical trial wins across several of these niches, particularly in lung cancer -- the leading cause of cancer death worldwide -- would likely send BioNTech stock much higher. But does any of that make the stock a strong buy? "No-brainer" is likely too optimistic.
A lot could go wrong with BioNTech stock, including clinical and regulatory setbacks for some of its leading candidates. The vaccine maker also has a market cap of $25.4 billion as of writing. For a biotech company that generates little revenue and is consistently unprofitable, that can seem like a lot. But the market is betting on BioNTech's deep pipeline, so if the company fails to meet Wall Street's expectations, the stock will fall off a cliff. But even accounting for potential clinical setbacks, BioNTech looks somewhat attractive, especially given Moderna's clinical win that makes BioNTech's entire mRNA pipeline far more valuable. Given the breadth of BioNTech's pipeline, which gives it multiple shots at developing blockbuster products, the company could survive a few clinical trial failures. All good reasons why the stock looks attractive.
BioNTech ukončí středně pokročilou studii své experimentální mRNA vakcíny proti rakovině poté, co nezávislý výbor usoudil, že pacientům s kolorektálním karcinomem pravděpodobně nepomůže žít déle. Akcie firmy na americké burze v pátek klesly o 7,5 %.
BioNTech SE (22UAy.DE) said it will end a mid-stage study of its experimental mRNA cancer vaccine after an independent committee found the treatment was unlikely to help colorectal cancer patients live longer, sending the company's U.S.-listed shares 7.5% lower on Friday.
The trial was testing whether the immunotherapy, autogene cevumeran, prevented a recurrence in patients with high-risk, mid-stage colorectal cancer who had already undergone surgery but still had traces of cancer DNA in their blood.
BioNTech's trial failure comes days after Merck (MRK.N) and Moderna (MRNA.O) said their mRNA-based vaccine helped prevent the return and spread of melanoma in a trial of more than 1,000 patients whose tumors were removed surgically but who had a high risk of recurrence.
That success had raised hopes for similar mRNA-based vaccines, lifting shares of BioNTech 20% on the day.
The committee responsible for overseeing the safety and integrity of BioNTech's trial identified a "numerical imbalance" in overall survival between the patient groups in the study. It said continuing the trial was unlikely to show the vaccine was effective.
Analysts said the "numerical imbalance" likely meant more deaths occurred in the vaccine group than the control group.
BioNTech did not respond to a request for comment.
"Today's update is more concerning than a conventional futility stop given the numerical (overall survival) imbalance, although the magnitude remains unclear," BMO Capital Markets analyst Evan Seigerman said in a note.
The trial evaluated whether the vaccine alone, given after surgery and three months of chemotherapy, could prevent recurrence in high-risk patients compared to standard watchful waiting.
CHALLENGES FOR MRNA VACCINES IN SOME TUMORS
BioNTech, a German vaccine maker, which is partnering with Roche's (ROPC.S) Genentech for the mRNA-based cancer vaccine, said that its decision to drop the study would not affect its other trial involving pancreatic cancer patients. Data from this study is expected in 2031.
Analysts said the failure is a negative signal for mRNA vaccines in "cold" tumors historically resistant to immunotherapy, like colorectal and pancreatic cancers, unlike "hot" tumors such as melanoma where Moderna succeeded.
This could also dim prospects for BioNTech's remaining pancreatic trial, despite its use of combination therapy with Roche's Tecentriq, analysts said.
BioNTech's vaccine, autogene cevumeran, is personalized to deliver instructions that teach the immune system to recognize each patient's specific tumor cells. The Merck-Moderna vaccine is similarly designed to target mutations unique to an individual patient's tumor.
The setback will likely accelerate BioNTech's strategic shift toward its non-mRNA pipeline, particularly its antibody-drug conjugates (ADCs) and bispecific cancer therapies, such as the experimental drug pumitamig.
BioNTech is also developing other mRNA-based cancer therapies, including BNT113 for head and neck cancer. Interim data from this study is expected later this year.
Moderna klesá o 18 % na 142,70 USD po včerejším 177% rally, protože trh vybírá zisky po úspěchu fáze 3 u personalizované mRNA vakcíny proti rakovině. BioNTech odepisuje 4 % na 108,39 USD a Merck 1 % na 150,63 USD.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock are down 18% to $142.70 in Thursday midday trading, unwinding a meaningful piece of Wednesday’s historic 177% rally. The reversal follows a Phase 3 win for Moderna’s personalized cancer vaccine, a result that repriced Moderna stock so violently in one session that a retrace looked close to inevitable.
BioNTech (NASDAQ:BNTX) stock is falling 4% to $108.39 as the German mRNA developer hands back part of its own read-across rally. BioNTech shares had entered Thursday up 19% year to date (YTD) on enthusiasm around the broader mRNA oncology platform.
Merck (NYSE:MRK) stock is slipping 1% to $150.63, a barely perceptible move for the pharma giant despite co-owning the same pivotal trial. Merck shares were still up 47% YTD heading into Thursday’s session.
The iShares Biotechnology ETF (NASDAQ:IBB) is down 2% to $213.64, while the Invesco QQQ Trust (NASDAQ:QQQ) is down 0.5% to $712.41. Biotech is taking the heavier hit today, and Moderna sits inside IBB as a holding, so an 18% decline in a single large constituent pulls the fund down with it.
Cancer Vaccine Win Sparks a Two-Day Roundtrip Moderna and Merck announced that intismeran, their personalized mRNA cancer vaccine, hit its primary endpoint in a Phase 3 trial. The readout showed a meaningful reduction in melanoma recurrence in patients whose tumors had already been surgically removed.
The combination arm paired intismeran with Merck’s Keytruda against Keytruda alone. Patients on the combination lived meaningfully longer without their cancer returning or spreading, validating years of Phase 2 signals previously reported at ASCO 2026.
Why the Rally Reversed So Hard JPMorgan’s Jessica Fye framed the setup on Moderna stock bluntly, writing that the firm sees “success in adj melanoma as priced in with the stock sitting at ~$25bn market cap prior to the news,” and that “we see the read-across to other indications as critical.” That framing captures why the Moderna trade is giving so much back today.
Bank of America’s Alec Stranahan struck a more constructive tone, calling the result “a watershed moment for Moderna, in our view, effectively allowing the company to diversify away from infectious disease and potentially easing persistent capital overhangs.” Citigroup’s Geoff Meacham cautioned that full validation depends on the complete dataset, potentially due at the ESMO conference in Madrid running October 23 to 27.
Same Trial, Very Different Materiality The split between Moderna and Merck shares is a clean way to read Thursday’s tape. Moderna carries a market cap of $56.18 billion, and a Phase 3 adjuvant melanoma win reshapes what Moderna is as a business. It hands the company a credible oncology franchise on top of its existing infectious-disease base.
Merck carries a market cap of $371.63 billion with Keytruda already anchoring the company’s oncology portfolio. The same trial result barely registers in Merck stock because the incremental economics are small relative to a Keytruda franchise already generating billions of dollars per quarter across a long list of approved indications.
BioNTech is running its own individualized mRNA cancer immunotherapy, autogene cevumeran, in partnership with Genentech, in adjuvant colorectal and pancreatic settings. BioNTech shares rallied earlier in the week on the platform read-across for mRNA oncology, and BioNTech stock is now handing some of that enthusiasm back. Readers interested in the wider pharma tape can see our prior coverage on which drugmaker stock has dominated in 2026.
What to Watch Next The unresolved question is whether the melanoma result reads across to other tumor types, since the full Moderna dataset has not been presented publicly yet. Traders can watch for the complete data drop at ESMO in Madrid in late October, the next scheduled catalyst that could either confirm or complicate the bull case on Moderna stock.
Position sizing on Moderna stock matters more than direction here. The single-session round trip shows how narrow the tape can get around one readout, and a moderate weighting keeps a portfolio’s exposure to the next data point manageable while the tumor-type read-across question on Moderna’s platform stays open.
Contact [email protected] for any questions or corrections.
BioNTech na WCLC představí první data z kombinace pumitamigu s elfetabart drozuntecanem u pokročilého karcinomu plic. Firma zároveň ukáže aktualizovaná data o celkovém přežití ze stage 1 fáze 3 u gotistobartu.
Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNTech’s leadership in novel-novel combination treatment strategiesUpdated overall survival data for gotistobart from the PRESERVE-003 Phase 3 clinical trial will add to the growing body of evidence for this chemotherapy-free treatment approach in the second- and later-line treatment of advanced squamous non-small cell lung cancer following prior immunotherapyBioNTech is advancing a diversified development program in lung cancer treatment spanning more than 16 ongoing clinical trials across subtypes, biomarkers and treatment settings, including five ongoing Phase 3 clinical trials and two novel-novel combination trials MAINZ, Germany, August 20, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data from its diversified development program in lung cancer treatment at the IASLC 2026 World Conference on Lung Cancer (“WCLC”) in Seoul, Republic of Korea, from September 12-15, 2026.
The breadth of data highlights the latest progress across key strategic assets, pumitamig (BNT327/BMS986545) and gotistobart (BNT316/ONC-392), as well as BioNTech’s mRNA-based immunotherapy approaches, highlighting the strength of BioNTech’s lung cancer treatment pipeline. Additionally, a late breaking oral presentation will detail data from the novel-novel combination trial of pumitamig with the investigational B7H3-targeted antibody-drug conjugate (“ADC”) elfetabart drozuntecan (elfe-D or BNT324/DB-1311), representing the first combination data for any PD-(L)1xVEGF bispecific immunomodulator and an ADC in lung cancer.
“Progress in lung cancer care means both improving treatment outcomes for patients and, importantly, finding better options for more patients who still do not sufficiently benefit from current standard therapies,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “The data we are presenting at this year’s WCLC provide further clinical evidence for our late-stage assets, gotistobart and pumitamig, and help to define the role of next-generation immunomodulators in addressing unmet medical needs in lung cancer. We are also presenting the first clinical evidence from a novel-novel treatment combination in lung cancer as part of our evaluation of pumitamig as a potential backbone for combination strategies of complementary mechanisms. Taken together, these data will inform the next steps in our clinical development programs and our broader efforts to expand treatment options for patients.”
Highlights from BioNTech’s presentations at WCLC 2026:
Novel-novel combination trial of pumitamig, developed in collaboration with Bristol Myers Squibb Company (“BMS”), and elfetabart drozuntecan, developed in collaboration with Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”):
Advanced/metastatic SCLC and NSCLC: First data from the global Phase 1/2 trial (NCT06892548) evaluating pumitamig in combination with the B7H3-targeting ADC elfetabart drozuntecan in patients with advanced or metastatic small cell lung cancer (“SCLC”) and NSCLC will be presented for this novel-novel treatment combination approach, underlining BioNTech’s leadership in novel-novel combination treatment strategies. Gotistobart – a tumor microenvironment-selective regulatory T cell depletion candidate targeting CTLA-4, developed in collaboration with OncoC4, Inc. (“OncoC4”):
2L+ squamous NSCLC: Updated overall survival data from stage 1 of the PRESERVE-003 Phase 3 clinical trial (NCT05671510) of gotistobart in patients with squamous non-small cell lung cancer (“NSCLC”) who progressed on prior PD-(L)1 inhibitor treatment will be presented. The results further contribute to the growing body of evidence for this chemotherapy-free treatment approach. The pivotal stage 2 part of the trial is ongoing. All abstracts are available through the WCLC website. Further information on BioNTech’s lung cancer pipeline can be accessed here.
Full presentation details:
CandidateAbstract TitleAbstract Number/Presentation DetailsPumitamig + elfetabart drozuntecanPumitamig (PD-L1 x VEGF-A bsAb) + Elfetabart Drozuntecan (Elfe-D, B7H3 ADC) in Patients with Advanced/Metastatic Lung Cancer (NSCLC or SCLC)Abstract # OA14.01
Oral Presentation
The Breakthrough Immunotherapy for Advanced NSCLC
Sep 15, 2026: 12:30 - 01:45pm KSTPumitamigFirst-line Pumitamig (PD-L1 × VEGF-A bsAb) Plus Chemotherapy in Unresectable Malignant Mesothelioma: Long-term PFS and OSAbstract #MO04.09
Mini Oral
Novel Therapeutics and Molecular Insights in Thymic Malignancies and Pleural Mesothelioma
Sep 13, 2026: 4:45 - 6:00pm KSTROSETTA Lung‑201: A Phase 3 Trial of Pumitamig Monotherapy vs Durvalumab in Unresectable Stage III NSCLC Post-ChemoradiationAbstract #P2.330
Poster
Clinical Trials in Progress
Sep 14, 2026: 10:30am - 12:00pm KSTROSETTA Lung-202: A Phase 3 trial of first-line pumitamig monotherapy vs pembrolizumab in locally advanced/metastatic NSCLCAbstract #P2.355
Poster
Clinical Trials in Progress
Sep 14, 2026: 10:30am - 12:00pm KSTGotistobartGotistobart vs Docetaxel in Metastatic Squamous NSCLC After PD-(L)1 Progression: Updated Overall Survival of the stage 1 of PRESERVE-003Abstract #MO07.04
Mini Oral
Novel Immunotherapeutic Strategies in mNSCLC
Sep 14, 2026: 5:00 - 6:15pm KSTBNT116Neoadjuvant BNT116 + Cemiplimab + Carboplatin + Paclitaxel in Resectable NSCLC: Preliminary Results From a Phase I TrialAbstract #MO06.03
Mini Oral
Emerging Precision Approaches in Perioperative Therapy for Resectable NSCLC Integrating Targeted Therapy, Immunotherapy, Biomarkers, and Multimodal Strategies
Sep 14, 2026: 3:30 - 4:45pm KST
About BioNTech in Lung Cancer Treatment
Lung cancer is one of BioNTech’s key focus areas. Through a diversified portfolio of investigational next-generation immunomodulators, ADCs and mRNA-based cancer immunotherapies, the Company is pursuing multiple approaches designed to address significant unmet needs for patients across lung cancer subtypes, histologies and treatment settings. BioNTech’s clinical pipeline encompasses both monotherapies and combinations with standard of care treatments, as well as novel-novel combination regimens aimed at delivering differentiated therapeutic profiles for the treatment of patients with lung cancer. With 16 ongoing lung cancer trials, including five pivotal Phase 3 and two novel-novel combination trials, BioNTech is advancing a comprehensive development strategy with the aim of improving outcomes for patients across the continuum of lung cancer.
About BioNTech
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.
For more information, please visit www.BioNTech.com.
BioNTech Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the initiation, timing, progress and results of BioNTech’s research and development programs in oncology, including the targeted timing and number of additional potentially registrational trials; BioNTech’s and its collaborators’ current and future preclinical and clinical trials in oncology, including the investigational bispecific immunomodulator pumitamig (BNT327/BMS986545) in unresectable malignant mesothelioma, the investigational anti-CTLA-4 antibody gotistobart (BNT316/ONC-392) in metastatic squamous NSCLC, the investigational B7H3-targeted ADC elfetabart drozuntecan (BNT324/DB-1311) in combination with pumitamig in (N)SCLC, and the investigational mRNA cancer immunotherapy candidate BNT116 in resectable NSCLC; the nature and characterization of and timing for release of clinical data across BioNTech’s platforms, which is subject to peer review, regulatory review and market interpretation; the planned next steps in BioNTech’s pipeline programs, including, but not limited to, statements regarding timing or plans for initiation or enrollment of clinical trials, or submission for and receipt of product approvals and potential commercialization with respect to BioNTech’s product candidates; and the potential safety and efficacy of BioNTech’s product candidates. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.
The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the ability to produce comparable clinical results in future clinical trials; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for its product candidates; discussions with regulatory agencies regarding timing and requirements for additional clinical trials; the impact of tariffs and escalations in trade policy; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech’s and its collaborators’ ability to commercialize and market its product candidates, if approved; BioNTech’s ability to manage its development and related expenses; regulatory and political developments; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time.
You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended June 30, 2026 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.
BioNTech jmenovala Guida Oelkerse novým generálním ředitelem, který převezme vedení nejpozději 1. února 2027. Firma tím míří k přechodu od covidu k širšímu onkologickému portfoliu.
BioNTech (BNTX +0.03%) is entering a new chapter. The company has named Guido Oelkers, the longtime CEO of Swedish rare-disease company Sobi, as its next chief executive. Oelkers will officially take over by Feb. 1, 2027, succeeding co-founder Uğur Şahin, who helped transform BioNTech into one of the world's best-known biotechnology companies during the COVID-19 pandemic.
To be sure, BioNTech is no longer primarily a COVID vaccine company. Vaccine sales continue to decline as pandemic demand fades, and management recently lowered its 2026 revenue guidance to a range of $1.85 billion to $2.19 billion. Second-quarter revenue fell nearly 60% year over year to $121.8 million, while the company's quarterly net loss widened to more than $946.3 million as it continued investing heavily in research and development.
Today's Change
(
0.03
%) $
0.03
Current Price
$
92.77
Orchestrating a transition It should be understood that Guido Oelkers isn't coming in to rescue a struggling business. He's being brought in to help transition BioNTech from a company built around one blockbuster product into one with a diversified oncology pipeline.
Image source: Getty Images.
During his nine years leading Sobi, Oelkers expanded the rare-disease drugmaker through acquisitions, commercial launches, and international growth. That experience could prove valuable as BioNTech prepares for multiple potential product launches later this decade.
Moving forward, much of the stock's performance will continue to be driven primarily by clinical trial results, regulatory approvals, and whether its sizable oncology pipeline can eventually replace declining COVID vaccine revenue. BioNTech has dozens of clinical programs spanning mRNA cancer vaccines, antibody-drug conjugates, and cell therapies, but bringing those products to market remains the company's biggest challenge.
In that context, Oelkers' appointment looks less like a dramatic strategic shift and more like a planned transition. BioNTech appears to be looking for an experienced commercial executive to guide the next phase of its evolution. Certainly, Oelkers checks all the boxes.
Jeff Siegel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BioNTech Se. The Motley Fool has a disclosure policy.
BioNTech ve 2. čtvrtletí vykázala tržby 106 milionů EUR, meziročně méně z 261 milionů EUR, a snížila celoroční výhled tržeb na 1,6 až 1,9 miliardy EUR. Důvodem je slabší poptávka po vakcíně proti COVID-19.
4 Reasons Pfizer Could Be a Value Play You Can't MissBioNTech NASDAQ: BNTX reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year quarter also benefited from a one-time compensation payment from Pfizer related to its decision to opt out of a shingles vaccine development program.
The company lowered its full-year revenue outlook to €1.6 billion to €1.9 billion, citing softer-than-expected global COVID-19 vaccine demand, Germany’s planned use of previously manufactured vaccine inventory for the upcoming season, and the delayed timing of an out-licensed research-and-development milestone. BioNTech expects most of its 2026 revenue in the second half, including a €613 million collaboration payment from Bristol Myers Squibb expected in the third quarter.
Get BioNTech alerts:
CEO Transition and Oncology Strategy Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?BioNTech announced that Guido Oelkers will become chief executive officer by Feb. 1 at the latest. Helmut Jeggle, chairman of the supervisory board, said Oelkers was selected for his strategic leadership, experience scaling global biopharmaceutical businesses and record of developing innovation-driven organizations.
Oelkers most recently served as CEO of Sobi, where Jeggle said he more than quadrupled revenue over nine years. Current CEO and co-founder Ugur Sahin said he will remain actively involved in preparing for Oelkers’ onboarding and characterized the transition as part of BioNTech’s evolution from a research-focused organization into a multi-product biopharmaceutical company.
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?Sahin said BioNTech is advancing a tumor-focused oncology strategy spanning next-generation immunomodulators, antibody-drug conjugates, or ADCs, and mRNA cancer immunotherapies. The company is targeting more than 17 late-stage and pivotal-trial readouts through 2030 and beyond.
Lung Cancer Programs Advance Chief Medical Officer and co-founder Özlem Türeci highlighted progress for pumitamig, BioNTech’s investigational bispecific immunomodulator targeting PD-L1 and VEGF-A that is being developed with Bristol Myers Squibb. The company is running four registrational lung-cancer programs for the candidate, including trials in small cell lung cancer, first-line non-small cell lung cancer, PD-L1-high non-small cell lung cancer and unresectable stage 3 non-small cell lung cancer.
At the American Society of Clinical Oncology meeting in June, BioNTech presented global phase II data from ROSETTA-Lung 02, which is evaluating pumitamig plus chemotherapy in previously untreated advanced non-small cell lung cancer. Among 40 evaluable patients, the combination generated unconfirmed and confirmed overall response rates of 72.5% and 62.5%, respectively, according to Türeci.
In patients with PD-L1 tumor proportion scores below 1%, the confirmed objective response rate was 47.6%. It was 77.8% among patients with scores between 1% and 49%, while all six patients with scores of at least 50% responded. Türeci said the safety profile was manageable, with no new safety signals, and that the results support the ongoing global phase III program.
BioNTech also expects a first interim analysis for gotistobart in late 2026 in pivotal-stage testing for metastatic squamous non-small cell lung cancer. Gotistobart is a selective regulatory T-cell-depleting CTLA-4 antibody being developed with OncoC4. In the non-pivotal first stage of the PRESERVE-003 study, Türeci said gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival had not been reached in the gotistobart arm, compared with about 10 months for docetaxel.
ADC and mRNA Programs The company dosed the first patient in a phase III study of elfetabart drozuntecan, formerly known as BNT324, in taxane-naive metastatic castration-resistant prostate cancer. The B7-H3-targeting ADC is being developed with DualityBio and is being tested against docetaxel in patients whose disease progressed after second-generation androgen receptor pathway inhibitors.
Sahin said more than 1,000 patients have received the ADC across more than 10 tumor types, including 400 treated in combination with pumitamig. He said the company has seen durable disease control and a tolerable safety profile, including no significant interstitial lung disease events observed so far among patients treated for more than a year.
BioNTech expects to present data later in 2026 from a phase I/II trial of pumitamig plus BNT324 in advanced non-small cell and small cell lung cancers. Türeci described the dataset as the first clinical data for a PD-L1/VEGF-A bispecific antibody combined with an ADC in lung cancer.
In mRNA cancer immunotherapy, enrollment has been completed in a randomized phase II trial of autogene cevumeran in high-risk stage 2 or stage 3 colorectal cancer. An independent data safety monitoring board reviewed an interim analysis in June and recommended continuing the trial without modification. BioNTech expects the final, event-driven analysis in 2027.
The company also expects a phase III progression-free-survival interim analysis later this year for BNT113, its HPV16-targeting mRNA immunotherapy being tested with pembrolizumab in first-line, PD-L1-positive HPV16-positive head and neck cancer.
Guidance, Expenses and Capital Allocation BioNTech reported adjusted research-and-development expense of €477 million in the second quarter, down from €509 million a year earlier, reflecting portfolio prioritization and favorable partner cost-sharing effects. Adjusted selling, general and administrative expense rose to €198 million from €137 million, driven by investments in operational systems, prelaunch activities and the inclusion of CureVac operations following the merger.
For 2026, the company now expects adjusted R&D expense of €2 billion to €2.3 billion, while maintaining adjusted SG&A guidance of €700 million to €800 million. BioNTech ended the quarter with €16.6 billion in cash equivalents and security investments.
CFO Ramon Zapata said the company has repurchased $152 million of shares under its up-to-$1 billion repurchase authorization. He said BioNTech’s capital-allocation priorities remain funding its priority pipeline and commercial capabilities, maintaining flexibility for external opportunities, and returning capital to shareholders.
About BioNTech (NASDAQ:BNTX)BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.
BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in BioNTech Right Now?Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
BioNTech plant building in Marburg, Germany, May 6, 2026. REUTERS/Fabian Bimmer Purchase Licensing Rights, opens new tab
CompaniesAug 3 (Reuters) - German biotech firm BioNTech (22UAy.DE), opens new tab said on Monday that Sobi's (SOBIV.ST), opens new tab CEO Guido Oelkers will succeed Ugur Sahin as its chief executive.
Oelkers will take on the role from February 1, 2027 at latest, the company said, after serving as CEO at the Stockholm-listed biopharmaceutical company since 2017.
The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.
BioNTech announced in March its two co-founders and leading executives, Sahin and Chief Medical Officer Oezlem Tuereci, would leave the COVID-19 vaccine maker by the end of the year to start a new venture.
Reporting by Linda Pasquini, Editing by Ludwig Burger
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Evropská komise schválila aktualizovanou vakcínu Pfizer a BioNTech proti COVID-19 pro sezónu 2026–2027, cílenou na variantu XFG. Povolení platí ve všech 27 zemích EU i na Islandu, v Lichtenštejnsku a Norsku.
Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globallyVaccine demonstrates a favorable safety and efficacy profile Shipping will begin soon to ensure rapid access of this season’s vaccine NEW YORK and MAINZ, GERMANY, July 29, 2026 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force (ETF) of the European Medicines Agency (EMA) to update COVID-19 vaccines to target the XFG variant of the JN.1 lineage for the 2026-2027 season. The ETF stated that “the evidence suggests that targeting XFG would provide the best protection against COVID-19.”1
The marketing authorization is valid in all 27 European Union (“EU”) Member States, as well as Iceland, Liechtenstein and Norway. Pfizer and BioNTech have already initiated manufacturing of the monovalent XFG-adapted COVID-19 vaccine at risk to ensure supply readiness in anticipation of the respiratory disease season, when the demand for COVID-19 vaccination is expected to increase. EU Member States as well as Norway, will be supplied either via the EC contract or according to individual country government policies.
The EC approval follows the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommendation from July 23, 2026 based on the cumulative body of evidence previously submitted by Pfizer and BioNTech that includes clinical, non-clinical and real-world data supporting the safety and efficacy of the Pfizer and BioNTech COVID-19 vaccine as well as manufacturing/quality and non-clinical data showing that the monovalent XFG-adapted COVID-19 vaccine generated strong immune responses against currently circulating SARS-CoV-2 lineages, including XFG, XFG.1.1, NB.1.8.1, PQ.17, PQ.2.8.1 and other contemporary lineages.2
The companies have also submitted data for the updated COVID-19 vaccine to regulatory authorities around the world. The companies are continuing to monitor the evolving epidemiology of COVID-19 in preparation to meet global public health needs.
The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies. BioNTech is the Marketing Authorization Holder for the Pfizer-BioNTech COVID-19 vaccine and its adapted vaccines in the United States, the EU, the United Kingdom, and other countries, and the holder of emergency use authorizations or equivalents in other countries.
EU SUMMARY OF PRODUCT CHARACTERISTICS
Please see here for the full Summary of Product Characteristics for the Pfizer-BioNTech COVID-19 vaccine.
IMPORTANT SAFETY INFORMATION
You or your child should NOT get COMIRNATY® (COVID-19 Vaccine, mRNA) if you or your child had a severe allergic reaction after a previous dose of COMIRNATY or any Pfizer-BioNTech COVID-19 vaccine or to any ingredient in these vaccinesThere is a remote chance that COMIRNATY could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose. For this reason, the vaccination provider may ask you or your child to stay at the place where you or your child received the vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include: Difficulty breathingSwelling of the face and throatA fast heartbeatA bad rash all over the bodyDizziness and weakness Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines, including COMIRNATY and Pfizer-BioNTech COVID-19 vaccines. Myocarditis and pericarditis following administration of mRNA COVID-19 vaccines have occurred most commonly in males 12 years through 24 years of age. In most of these people, symptoms began within a week following vaccination. You should seek medical attention right away if you or your child have any of the following symptoms after receiving the COMIRNATY, particularly during the 2 weeks after receiving a dose of the vaccine: Chest painShortness of breathFeelings of having a fast-beating, fluttering, or pounding heartAdditional symptoms, particularly in children, may include: FaintingUnusual and persistent fatigue or lack of energyPersistent vomitingPersistent pain in the abdomenUnusual and persistent cool, pale skin Fainting can happen after getting injectable vaccines including COMIRNATY. Your vaccination provider may ask you to sit or lie downPeople with weakened immune systems may have a reduced immune response to COMIRNATYVaccination with COMIRNATY may not protect all people who receive the vaccine Before getting COMIRNATY, tell your vaccination provider about all of your or your child’s medical conditions, including if you or your child:
have any allergieshad a severe allergic reaction after receiving a previous dose of any COVID-19 vaccinehave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)have a feverhave a bleeding disorder or are on a blood thinnerare immunocompromised or are on a medicine that affects your immune systemare pregnant, plan to become pregnant, or are breastfeedinghave received another COVID-19 vaccinehave ever fainted in association with an injection Additional side effects that have been reported with COMIRNATY or Pfizer-BioNTech COVID-19 vaccines include:
Non-severe allergic reactions such as rash, itching, hives, or swelling of the faceInjection site reactions: pain, swelling, redness, arm painGeneral side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph nodes (lymphadenopathy), decreased appetite, diarrhea, vomiting, dizziness These may not be all the possible side effects of COMIRNATY. Ask your or your child’s healthcare provider about any side effects that concern you.
In addition, you can report side effects to Pfizer Inc. at 1-800-438-1985 or www.pfizersafetyreporting.com.
Please click here for full Prescribing Information and Patient Information for COMIRNATY.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Pfizer Disclosure Notice
The information contained in this release is as of July 29, 2026. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about the Pfizer-BioNTech COVID-19 vaccine, including its potential benefits, manufacturing and supply, expectations regarding demand for COVID-19 vaccination and an approval by the European Commission to update the marketing authorization for the Pfizer-BioNTech COVID-19 vaccine to target the XFG variant of the JN.1 lineage for the 2026-2027 season, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of the Pfizer-BioNTech COVID-19 vaccine; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when applications may be filed with regulatory authorities in particular jurisdictions for the Pfizer-BioNTech COVID-19 vaccine for any potential indication, including for the 2026-2027 COVID-19 vaccine formula; whether and when any such applications that may be pending or filed for the Pfizer-BioNTech COVID-19 vaccine may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether the Pfizer-BioNTech COVID-19 vaccine will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of the Pfizer-BioNTech COVID-19 vaccine; risks and uncertainties related to changes to vaccine or other healthcare policy in the EU, the U.S. or other jurisdictions; the risk that demand for any products may be reduced or no longer exist or not meet expectations which may lead to reduced revenues or excess inventory on-hand and/or in the channel or other unanticipated charges; uncertainties related to recommendations and coverage for, and the public’s adherence to vaccines, boosters, treatments or combinations; risks related to our ability to accurately predict or achieve our revenue forecasts for the Pfizer-BioNTech COVID-19 vaccine or any potential future COVID-19 vaccines; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on our business, operations and financial results; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
About BioNTech
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.
For more information, please visit www.BioNTech.com.
BioNTech Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer; regulatory submissions and regulatory approvals or authorizations, including an approval by the European Commission to update the marketing authorization for the Pfizer-BioNTech COVID-19 vaccine to target the XFG variant of the JN.1 lineage for the 2026-2027 season; expectations regarding manufacturing, distribution and supply; qualitative assessments of available data and expectations of potential benefits, including the adapted vaccine’s response against multiple SARS-CoV-2 lineages, including the XFG variant of the JN.1 lineage and other circulating sublineages; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment; and expected regulatory recommendations to adapt vaccines to address new variants or sublineages. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.
The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events, and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech’s pricing and coverage negotiations with governmental authorities, private health insurers and other third-party; the future commercial demand and medical need for initial or annual booster doses of a COVID-19 vaccine; the impact of tariffs and escalations in trade policy; the availability of raw materials to manufacture a vaccine; our vaccine’s formulation, dosing schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery; competition from other COVID-19 vaccines or related to BioNTech’s other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for BioNTech’s product candidates; the ability of BioNTech’s COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech’s development candidates and investigational medicines; the impact of COVID-19 on BioNTech’s development programs, supply chain, collaborators and financial performance; unforeseen safety issues and potential claims that are alleged to arise from the use of BioNTech’s COVID-19 vaccine and other products and product candidates developed or manufactured by BioNTech; BioNTech’s and its collaborators’ ability to commercialize and market BioNTech’s COVID-19 vaccine and, if approved, its product candidates; BioNTech’s ability to manage its development and related expenses; regulatory developments in the United States and other countries; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time.
You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech's Report on Form 6-K for the period ended March 31, 2026, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at https://www.sec.gov/. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.
BioNTech se odklání od COVID a sází na onkologii, kde má přes 25 probíhajících studií ve fázi 2 nebo 3. Největší nadějí je pumitamig s Bristol Myers Squibb, který by mohl získat schválení během několika let.
BioNTech (BNTX +0.33%) rose to prominence several years ago thanks to its role in the coronavirus market. The company developed Comirnaty, one of the best-selling COVID-19 vaccines, with Pfizer (PFE +0.77%). However, vaccination rates have dropped significantly due to a combination of factors, including stricter market regulations. As a result, BioNTech's coronavirus business hasn't performed well recently. The good news is that the company's future no longer depends on its work in this industry. There is another much larger area BioNTech is targeting. Here's what investors need to know.
Image source: Getty Images.
The industry's largest therapeutic area The weight-loss market is grabbing headlines for its rapid growth. But the largest area in the industry by annual sales remains oncology. There are several reasons for that. Let's consider four of them. First, cancer is one of the world's leading causes of death. According to some estimates, in the U.S., one person in three will be diagnosed with cancer at some point in their lives. So, it is a fairly common disease with a significant annual death toll. Second, the oncology market is massive. There are dozens of types of cancer, and some corners of the industry remain underserved, which can attract even more drugmakers.
Third, because cancer is a life-threatening condition, regulators often grant cancer medicines in development special designations that can help speed up approval, a factor that incentivizes drugmakers to develop more of them. Lastly, cancer medicines often command high prices and can sometimes be administered over years. The cancer therapeutics space will continue to expand, and, according to some estimates, it will be worth $516.2 billion by 2035, with a compound annual growth rate of 9.3% over that period. That's the market where BioNTech is looking to carve out a meaningful niche. Can the company pull it off?
Today's Change
(
0.33
%) $
0.30
Current Price
$
92.13
BioNTech's exciting pipeline BioNTech has more than 25 phase 2 or phase 3 ongoing oncology clinical trials. This large pipeline should lead to at least a few approvals. Several of the company's products look particularly promising. Perhaps the most interesting is pumitamig, which BioNTech is developing in collaboration with Bristol Myers Squibb (BMY +1.23%). Pumitamig is a bispecific antibody, a class of medicines that bind to two different targets simultaneously, enabling it to direct the body's immune system to attack diseases like cancer more effectively than conventional antibodies.
Bispecific antibodies like pumitamig could gain significant traction in the coming years. The medicine has been dubbed a potential "Keytruda killer," or next-generation oncology medicines that could challenge Keytruda, currently the best-selling cancer drug on the market. Pumitamig is being investigated across cancers of the lung, kidney, breast, liver, colon, and rectum, among others. Pumitamig is well-positioned to earn approval within a couple of years and, eventually, generate well over $1 billion in annual sales. And that's just one of BioNTech's oncology candidates. Expect the company to improve its financial results significantly as it continues to make headway in this market.
Is BioNTech stock a buy? BioNTech's pipeline looks promising, even beyond its oncology-related work. The biotech is developing products in other areas, notably infectious diseases. It is working on vaccines for tuberculosis and even HIV. Clinical progress over the next few years could significantly strengthen its prospects. However, BioNTech's valuation is concerning. The stock is worth $23.2 billion, despite posting just $3.3 billion in revenue over the trailing-12-month period, and its sales are declining. The company isn't consistently profitable either.
The market appears to be placing a lot of faith in BioNTech's pipeline. That won't be a problem so long as the company's work in this area goes smoothly, but its share price could fall off a cliff at any sign of trouble. And there likely will be at least some signs of trouble -- it's hard for any biotech company to run a pipeline that large without encountering clinical or regulatory setbacks. My view is that, even though its pipeline looks exciting, BioNTech isn't attractive at current levels. Investors would be better off waiting for the stock to fall from its current levels before initiating a position.
Společnost Ark Invest Cathie Woodové prodala akcie BioNTech za zhruba 7,4 milionu USD a zůstalo jí jen 307 kusů. Akcie BioNTech letos klesly téměř o 4 % a za 12 měsíců o více než 17 %.
On July 7, Cathie Wood's Ark Genomic Revolution ETF (ARKG +0.39%) sold over 44,000 shares of BioNTech (BNTX 0.32%), a German immunotherapy maker. The next day, it sold over 78,000 shares, a transaction valued at around $7.4 million.
As of July 10, that left her asset management company with just 307 shares, valued at a little more than $28,000. Because Ark Invest holds positions worth millions of dollars and BioNTech is now the smallest holding in this entire exchange-traded fund (ETF), it may be fair to assume that Wood has moved on from BioNTech.
Image source: Getty Images.
What may have caused BioNTech to get the boot One thing to know about ARKG is that it's an actively managed ETF, so it's common for the fund to move in and out of stocks frequently.
Today's Change
(
0.39
%) $
0.16
Current Price
$
40.75
Because Wood's ETF has now sold most of its BioNTech shares, it appears to be moving on, freeing up capital for Ark Invest. BioNTech stock has underperformed this year; as of this writing, its price is down nearly 4% year to date and has dipped more than 17% over the last 12 months. But there are challenges ahead that could continue to send shares lower.
One is that revenue is expected to land somewhere between 2 billion euros ($2.2 billion) and 2.3 billion euros ($2.6 billion) in 2026, a significant decrease from the 2.9 billion euros ($3.3 billion) reported for 2025. That's largely due to an expected drop in revenue from its COVID-19 vaccine, developed in partnership with Pfizer.
Another financial issue is that BioNTech reported back-to-back net losses in 2024 and 2025, after a net profit of 900 million euros ($1 billion) in 2023. That trend of net losses will likely continue, as BioNTech already showed a net loss in its 2026 first-quarter earnings report.
There are also issues on the leadership front. BioNTech's co-founders, Uğur Şahin and Özlem Türeci, are leaving the company by the end of 2026. Şahin is the CEO, and Türeci is the chief medical officer, so those are significant roles to fill. What makes that leadership transition even more challenging is that BioNTech has been shifting its focus from vaccines to oncology treatments.
Today's Change
(
-0.32
%) $
-0.29
Current Price
$
89.79
Is it time to sell BioNTech? The move from Ark Invest is notable. While investors shouldn't automatically follow its lead in selling the stock, BioNTech is trying to overcome several challenges at once. The company has a promising clinical pipeline of more than 25 phase 2 or phase 3 trials in oncology, but it only has one commercial product -- that COVID vaccine with slumping sales. All of this is complicated by the need to find new leadership.
If you haven't invested yet, you may want to consider holding off on starting a position -- at least until new management is found and the drugs in the pipeline show more progress.
BioNTech podle Handelsblattu vedl důvěrná jednání s potenciálními kupci o čtyřech německých provozech, které chce uzavřít. Do prodeje má jít i JPT Peptides.
The logo of BioNTech is pictured at Biontech's research laboratory for individualised vaccines against cancer in Mainz, Germany, July 27, 2023. REUTERS/Wolfgang Rattay Purchase Licensing Rights, opens new tab
CompaniesBERLIN, July 3 (Reuters) - BioNTech (22UAy.DE), opens new tab has held confidential talks with potential buyers about the German sites that the COVID‑19 vaccine maker plans to close, which has now grown to four locations, the Handelsblatt newspaper reported on Friday.
The German company had said in May that it would close three sites in Germany - Idar-Oberstein, Marburg and Tuebingen - by the end of 2027, and also end operations in Singapore by the first quarter of next year, affecting up to 1,860 jobs.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
According to Handelsblatt, the Berlin-based BioNTech subsidiary JPT Peptides is also being put up for sale.
The maker of peptides used in immunology and drug discovery is no longer profitable, and BioNTech plans to close it by the end of this year, the report said, citing people familiar with the decisions.
BioNTech and JPT Peptides did not immediately respond to emailed requests for comment.
Writing by Miranda Murray; Editing by Lincoln Feast.
Our Standards: The Thomson Reuters Trust Principles., opens new tab
